Recruiting

Prognostic Biomarkers

Sponsor:

Dana-Farber Cancer Institute

Code:

NCT03683680

Conditions

Mesothelioma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

MPT Test

CLDN15/VIM Test

Study Details

Brief summary:

This research study is evaluating a new method for determining stage and prognosis of individuals with malignant pleural mesothelioma.

Conditions

Mesothelioma

Study ID

NCT03683680

Start date

Oct 31, 2018

Status verified date

Apr, 2026

Completion date

Oct 1, 2030

Anticipated

Primary completion date

Jan 1, 2030

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • All adult patients with a diagnosis of malignant pleural mesothelioma undergoing

  • diagnostic pleural biopsy
  • pleuroscopy
  • and/or VATS resections
  • Participants must be 18 years of age or older.

Exclusion Criteria:

-Any patient who is found to be unsuitable for

  • surgery,
  • treatment
  • diagnosis,

Study Design

Enrollment

240 participants

Anticipated

Intervention Model

Single group

Primary purpose

Diagnostic

Interventions and Outcome Measures

Arms

experimental: MRiS

  • The specimens to be collected will include at least five pleural biopsy samples
  • MPT test and the CLDN15/VIM test will be performed

Interventions

MPT Test

molecular expression tests at the RNA level using approximately 7 or more genes with RTPCR, nanostring or similar platforms

CLDN15/VIM Test

molecular expression tests at the RNA level using approximately 7 or more genes with RTPCR, nanostring or similar platforms

Primary outcome measure

  • Pre-treatment Prognostic Algorithm Validation [ Time Frame: 4 years ]

Central Contacts and Locations

Central contacts

Raphael Bueno, MD

617-732-5690rbueno@partners.org

Locations

Brigham and Women's Hospital

Recruiting

Boston, Massachusetts, United States, 02215

Contacts

Raphael Bueno, MD

617-732-5690rbueno@partners.org

Principal Investigator:

Raphael Bueno, MD

More Information

Sponsor

Dana-Farber Cancer Institute

Last update posted

May 5, 2026

Last verified

Apr, 2026

Keywords

  • Mesothelioma

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Dana-Farber Cancer Institute on 2026-05-05.